XML 160 R33.htm IDEA: XBRL DOCUMENT v3.25.3
Share-Based Compensation (Tables)
9 Months Ended 12 Months Ended
Sep. 30, 2025
Dec. 31, 2024
Share-Based Compensation [Abstract]    
Schedule of Company’s Stock Option Activity

The summary of the Company’s stock option activity is as follows:  

 

   Number of
Stock Options
   Weighted-
Average
Exercise Price
   Weighted-
Average
Remaining
Contractual
Life
 
Outstanding at December 31, 2024   

329,395

   $51.30    5.4 
Granted   8,080    9.60    10 
Exercised   
-
    
-
    
-
 
Forfeited/Expired/Cancelled   (114,840)   50.39    
-
 
Outstanding at September 30, 2025   222,635   $50.28    4.4 
Exercisable at  September 30, 2025   180,146   $51.85    4.4 

The summary of the Company’s stock option activity is as follows:

 

   Number of
Stock
Options
   Weighted-
Average
Exercise
Price
   Weighted-
Average
Remaining
Contractual
Life
 
Outstanding at December 31, 2023   369,092   $49.20    6.1 
Granted   
-
    
-
    
-
 
Exercised   
-
    
-
    
-
 
Forfeited/Expired/Cancelled   (39,698)  $30.90    
-
 
Outstanding at December 31, 2024   329,395   $51.30    5.4 
Exercisable at December 31, 2024   276,060   $51.30    5.4 
Schedule of Company’s Restricted Stock Unit Activity

The summary of the Company’s restricted stock unit activity is as follows:  

 

       Weighted-
Average
   Weighted-
Average
 
   Number of   Grant Date   Remaining 
   Shares   Fair Value   Vesting Period 
Unvested at December 31, 2024   739   $48.90    0.2 
Granted   16,667    9.60    2.6 
Vested   (142)   48.90    
 
Forfeited/Expired/Cancelled   (597)   48.90    
 
Unvested at September 30, 2025   16,667   $9.60    2.4 

The summary of the Company’s restricted stock unit activity is as follows:

 

   Number of
Shares
   Weighted-Average
Grant Date
Fair Value
   Weighted-Average
Remaining
Vesting Period
 
Outstanding at December 31, 2023   3,124   $      48.90    1.2 
Granted   
    
     
Vested   (2,386)   48.90     
Forfeited   
    
     
Outstanding at December 31, 2024   738   $48.90    0.2 
Schedule of Recorded Stock-Based Compensation Expense

The summary of the recorded stock-based compensation expense is as follows:

 

   Three Months Ended
September 30,
   Nine Months Ended
September 30,
 
   2025   2024   2025   2024 
                 
Research and development  $4   $11   $22   $62 
General and administrative   282    404    1,136    1,469 
Total stock-based compensation  $286   $415   $1,158   $1,531 

The summary of the recorded stock-based compensation expense is as follows:

 

   Years ended December 31, 
   2024   2023 
Research and development  $72   $118 
General and administrative   1,855    2,187 
Total stock-based compensation  $1,927   $2,305 
Schedule of Fair Value Assumptions of the Stock Options Granted to Employees, Directors and Nonemployees  

The assumptions that the Company used to determine the fair value of the stock options granted to employees, directors and nonemployees were as follows:

 

    Year ended
December 31,
2023
 
Risk-free interest rate     3.53 %
Expected term (in years)     6.3  
Expected volatility     71 %
Expected dividend yield     0 %